Biogen has entered into a multi-year research collaboration with Rodin Therapeutics. The collaboration will focus on therapies for central nervous system diseases, particularly neurodegenerative conditions such as Alzheimer's disease. As part of the agreement, Biogen will have the option to acquire Rodin at certain pre-defined milestones at pre-negotiated terms, including total upfront and milestone payments of up to $485 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
227.9 USD | -0.95% |
|
+0.04% | -11.83% |
Jul. 12 | Biogen, Eisai Get Approval for Leqembi in Israel for Treatment of Alzheimer's Disease | MT |
Jul. 12 | Piper Sandler Adjusts Biogen's Price Target to $313 From $335, Keeps Overweight Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.83% | 33.5B | |
+7.64% | 101B | |
+8.29% | 42.63B | |
+82.83% | 29.77B | |
-11.65% | 16.14B | |
+0.92% | 14.31B | |
-12.13% | 11.55B | |
+176.65% | 10.53B | |
+2.92% | 9.2B | |
-55.52% | 8.98B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Biogen Enters into Multi-Year Research Collaboration with Rodin Therapeutics